Effect of a Probiotic on the Female Genital Tract Microbiota of Participants With Fertility Disorders.

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-45
SponsorProbiSearch SL

About this trial

In the last decades, numerous publications have broken the old paradigm that considered the urogenital tracts as sterile, demonstrating that microorganisms present in the urogenital tract represent the 9% of the whole human microbiome. Healthy urogenital microbiome improves implantation rate and pregnancy outcomes, whereas 40% of dysbiosis prevalence is observed in women under assisted reproductive treatment (ART).

Infertility causes are associated with male, female, or combined failure. It has been shown that oral probiotic treatment, mainly with Lactobacillus, recovers a healthy vaginal microbiota without safety concerns.

An interventional, randomized, double-blind, placebo-controlled study will be conducted to confirm the positive effect of the commercial probiotic product Fertibiome® on the vaginal dysbiosis of couples or women with fertility disorders.

The duration of the study will be of 6 months approximately, including 6 months of product intake. In case of pregnancy during intervention, women will continue their participation until week 12 of gestation.

Participants will be randomly assigned to one of the two study groups: control group with placebo administration or probiotic administration group. Women will take 1 capsule every 12 hours and men 1 per day. In case of women participating alone they will take 1 capsule every 12 hours. In case of pregnancy, only women will continue taking 1 capsule per day for the first 12 weeks.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Couples or women with ages between 18 and 45 for woman and between 18 and 55 for man (in case of couple participation).

Couples or women with fertility disorders.

Couples or women undergoing IVF treatment or willing to start it.

Signature of the Informed Consent.

Disqualifiers

Women, not participating in the study with a couple, who have not undergone at least 4 cycles of artificial insemination with donor's sperm (AID) or 1 cycle of IVF without achieving evolutionary pregnancy.

Women with Body Mass Index (BMI) ≥ 30.

Azoospermia

Sperm motility (A + B) < 25%.

Trial design

Design model

Parallel

Treatments tested in this trial

  • Probiotic

    Dietary supplement

    * Women: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) every 12 hours for 6-months. In case of pregnancy: * Women: 1 capsule of probiotic per day for 12 weeks. * Men: 1 capsule of probiotic (Ligilactobacillus salivarius PS11610) per day for 6-months.

  • Placebo

    Dietary supplement

    * Women: 1 capsule of placebo every 12 hours for 6-months. In case of pregnancy: * Women:1 capsule of placebo per day for 12 weeks. * Men: 1 capsule of placebo per day for 6-months.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: ProbioticActive comparator 1 intervention
Group B: PlaceboPlacebo comparator 1 intervention

Trial outcomes

Primary outcomes

1

Percentage (%) of women with vaginal dysbiosis after 3 months of treatment.

The percentage of vaginal dysbiosis confirmed will be compared between groups of treatment.

Time frame
After 3 months of intervention.
2

Percentage (%) of women with vaginal dysbiosis after 6 months of treatment.

The percentage of vaginal dysbiosis confirmed will be compared between groups of treatment.

Time frame
After 6 months of intervention.

Secondary outcomes

1

Number of vaginal dysbiosis criteria in case of pregnancy confirmation.

Time frame
Up to 6 months.
2

Percentage (%) of women with vaginal dysbiosis.

Time frame
Before intervention.
3

Number of dysbiosis criteria per woman.

Time frame
Before intervention.
4

Number of dysbiosis criteria per woman.

Time frame
After 3 months of treatment pregnancy confirmation.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.